# Evaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic Dermatitis

> **NCT07054736** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhejiang Kanova Biopharmaceutical Co., LTD** · enrollment: 120 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** XKH001 Injection
- **DRUG:** XKH001 Placebo Injection

## Key facts

- **NCT ID:** NCT07054736
- **Lead sponsor:** Zhejiang Kanova Biopharmaceutical Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-31
- **Primary completion:** 2025-10-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07054736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07054736, "Evaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07054736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*